NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Character Biosciences

Character Biosciences

Private
Jersey City, New JerseyHealthcare & Life Scienceshttps://www.characterbio.com/

Last Round

Series B

Extension

Sep 17, 2025

Est. Valuation

$197M

Total Funding Raised

$138M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Character Biosciences is a biotechnology company that develops precision medicine and targeted therapies for progressive polygenic diseases, with an initial focus on ophthalmology.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Precision Medicine, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

precision medicinedrug discoverybiotechtarget validationophthalmologygenomicsai drug discoveryin silico drug discoverybiomarker discoveryclinical data analyticstherapeutic target identificationdrug development platformpatient stratificationai biocomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Character Biosciences Comps

Public and private peers based on sector, stage, and business model.

Character Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Character Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionSep 17, 2025
Series BMar 25, 2025
Series AMay 17, 2022
SeedMar 1, 2020

Character Biosciences Investors

Notable investors and investment history

Character Biosciences investors
InvestorRounds
S32Series A, Series B
Cantos VenturesSeries A, Seed
Innovation EndeavorsSeries B Extension, Series B, Series A
Lifeforce CapitalSeries A, Seed
Catalio Capital ManagementSeries B Extension, Series A, Series B
LUMA PartnersSeries B
Jefferson Life SciencesSeries B Extension, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 24, 2026

    Grew 16% QoQ, from 49 to 57 employees.

  • Jan 1, 2026

    Partnering with Bausch + Lomb to develop precision medicines for AMD.

Character Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Character Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Character Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersJersey City, New Jersey
Employee Range57
Year Founded2019
Last FundingSep 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.